» » The getfitinib picture that showed the whisker-like hairgrowth on the
» one
» » man’s nose, was probably in response to him getting too much sun on his
» » nose.
» »
» » I’d be willing to bet the house on that one. The two trichotic photos
» we
» » have seen with this product have come on places on the body that get
» » sunburnt most often (top of a bald man’s head, and the nose).
» »
» »
» » I was just ruminating on the subject, and that thought jumped out at
» me.
»
» Benji, I’m sorry to ask you this since I’m too lazy to go back on you’re
» old posts, but are planning to take getfinib orally or topically? Just
» curious, thanks.
»
» – Mr. F
TAGOHL,
3G has emailed me and told me that they cant accept paypal right now due to technical difficulties. They suggested I get to them using something called xoom.com. I'll have to check into them.
Ive tried ordering getfitinib powder, but since I dont have a “shipping company” (or a fax number), they wouldn’t send. Its a research entitity, and Im fairly certain they dont want to send this stuff to residential homes. Too bad too, because I could have bought five full grams of it pretty cheap as a powder.
Mr. F, I wanted to take it orally. Im not a topicals expert and am just as “all thumbs” as the next guy (lol).
TAGOHL,
I never mentioned this before, but a very very smart poster (pre-med student) who doesnt post anymore at HLT, mentioned that he had strange hair growth after getting a sunburn on his vertex. His name was Docjo77. He was a science guy and really knew his stuff. Potato protien was one of the EGF-antagonist mentioned in the FIRST patent. I wonder if someone got a sunburn and made it a priority to eat two or three full potato skins (potato protien is in the skin primarily), if he would see new hair. An EGF-inhibitor really need not be an expensive drug if it just inhibits that particular receptor without inhibiting wnt at the crucial three or four days. If I could nail this down.....it might be even easier than we think.
Here are all the EGF inhibitors mentioned in the first patent (I noticed they took all naturals out of the second patent. I’ll highlight the naturals):
[00063] In another embodiment, the inhibitor of an EGF or an EGF receptor is panirumumab. In another embodiment, the inhibitor is AG1478. In another embodiment, the inhibitor is nimotuzumab. In another embodiment, the inhibitor is an antibody that binds EGF or EGFR. In another embodiment, the inhibitor is HuMax-EGFR® (Genmab, Copenhagen, Denmark). In another embodiment, the inhibitor is cetuximab. In another embodiment, the inhibitor is IMC 11F8. In another embodiment, the inhibitor is matuzumab. In another embodiment, the inhibitor is SC 100. In another embodiment, the inhibitor is ALT 110. In another embodiment, the inhibitor is PX 1032. In another embodiment, the inhibitor is BMS 599626. In another embodiment, the inhibitor is MDX 214. In another embodiment, the inhibitor is PX 1041. In another embodiment, the inhibitor is any other inhibitor of an EGF or an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
[00064] In another embodiment, the compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell is an inhibitor of a tyrosine kinase activity of an EGF receptor. In another embodiment, the inhibitor is gefitinib. In another embodiment, the inhibitor is
P-7628-PC erlotinib. In another embodiment, the inhibitor is canertinib. In another embodiment, the inhibitor is leflunomide. In another embodiment, the inhibitor is A77 1726. In another embodiment, the inhibitor is pelitinib. In another embodiment, the inhibitor is ZD 1839. In another embodiment, the inhibitor is CL 3877S5. In another embodiment, the inhibitor is EKI 785. In another embodiment, the inhibitor is vandetanib. In another embodiment., the inhibitor is any other inhibitor of a tyrosine kinase activity of an EGF receptor known in the art. Each possibility represents a separate embodiment of the present invention.
[00065] In another embodiment, the EGF or EGFR antagonist is a carboxypeptidase inhibitor from potato (PCI) protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is a sprouty protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is an Argos protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is a lefty protein or a homologue, fragment or mimetic thereof. In another embodiment, the EGF or EGFR antagonist is an antibody that recognizes EGF or EGFR, or a fragment or mimetic thereof. Bi another embodiment, the EGF or EGFR antagonist is small molecule inhibitor that binds and reduces the activity of EGF or EGFR. In another embodiment^ the EGF or EGFR antagonist is CRMl 97. In another embodiment, the EGF or EGFR antagonist is IMC-C225 (ImClone Systems, New York. NY). In another embodiment, the EGF or EGFR antagonist is any other antagonist of EGF or EGFR known in the art. Each possibility represents a separate embodiment of the present invention.
Anybody know what IMC-C225 from Inclone Systems is???
How about HUMAX EGFR???
I wonder if those are drugs?